PMID- 21042697
OWN - NLM
STAT- MEDLINE
DCOM- 20110729
LR  - 20211020
IS  - 1475-1534 (Electronic)
IS  - 1471-4418 (Print)
IS  - 1471-4418 (Linking)
VI  - 19
IP  - 4
DP  - 2010 Dec
TI  - Effect of tiotropium on quality of life in COPD: a systematic review.
PG  - 315-25
LID - 10.4104/pcrj.2010.00067 [doi]
AB  - BACKGROUND: Chronic obstructive pulmonary disease (COPD) greatly affects quality 
      of life (QoL). Although QoL is a key concern for the patient, primary endpoints 
      in most clinical trials are objective measures of disease progression. METHODS: A 
      systematic review of double-blind randomised controlled trials was undertaken to 
      identify data relating to the effect of tiotropium on QoL in patients with COPD. 
      RESULTS: A total of 24 publications met the inclusion criteria. Compared with 
      placebo, in the majority of studies tiotropium statistically significantly 
      improved the St George's Respiratory Questionnaire (SGRQ) total score, although 
      improvement beyond the accepted minimum clinically important difference (MCID) of 
      4 units was only achieved in three studies, all of which were of less than nine 
      months' duration. Tiotropium also statistically significantly improved the 
      Transition Dyspnoea Index (TDI) focal score, equating to clinically meaningful 
      improvements, in almost all the studies that assessed TDI. In general, higher 
      proportions of patients receiving tiotropium achieved clinically meaningful 
      responses. The addition of other therapies (dual therapy, triple therapy) to 
      tiotropium provided benefits that exceeded the SGRQ MCID and provided further 
      benefit with regard to the TDI. CONCLUSIONS: Tiotropium improves QoL for patients 
      with COPD requiring long-acting bronchodilators, with other additional therapies 
      providing further benefits, depending on the population.
FAU - Kaplan, Alan
AU  - Kaplan A
AD  - Family Physician Airways Group of Canada, Richmond Hill, Ontario, Canada. 
      for4kids@gmail.com
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Prim Care Respir J
JT  - Primary care respiratory journal : journal of the General Practice Airways Group
JID - 101121543
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Scopolamine Derivatives)
RN  - XX112XZP0J (Tiotropium Bromide)
SB  - IM
MH  - Bronchodilator Agents/*therapeutic use
MH  - Humans
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy/psychology
MH  - *Quality of Life/psychology
MH  - Scopolamine Derivatives/*therapeutic use
MH  - Tiotropium Bromide
PMC - PMC6602263
COIS- AK is part of the speakers bureau for AstraZeneca, GlaxoSmithKline, Talecris, 
      Boehringer Ingelheim, Nycomed, Pfizer, and Purdue and has received funding for 
      meeting attendance from AstraZeneca and Merck Frosst. AK is on advisory boards 
      for Merck Frosst, Novartis, Purdue, and AstraZeneca; on the Health Canada section 
      of Allergic and Respiratory Therapeutics; also on the Public Health Agency of 
      Canada respiratory surveillance committee.
EDAT- 2010/11/03 06:00
MHDA- 2011/07/30 06:00
PMCR- 2010/12/01
CRDT- 2010/11/03 06:00
PHST- 2010/11/03 06:00 [entrez]
PHST- 2010/11/03 06:00 [pubmed]
PHST- 2011/07/30 06:00 [medline]
PHST- 2010/12/01 00:00 [pmc-release]
AID - pcrj-2010-04-0036-R2 [pii]
AID - 10.4104/pcrj.2010.00067 [doi]
PST - ppublish
SO  - Prim Care Respir J. 2010 Dec;19(4):315-25. doi: 10.4104/pcrj.2010.00067.